Telomir Pharmaceuticals, Inc.
$1.48
▼
-3.79%
2026-04-21 09:46:01
telomirpharma.com
NCM: TELO
Explore Telomir Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$49.85 M
Current Price
$1.48
52W High / Low
$3.1 / $1.05
Stock P/E
—
Book Value
$0.17
Dividend Yield
—
ROCE
-178.22%
ROE
-3.18%
Face Value
—
EPS
$-0.33
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
-0.73
Debt / Equity
8.01
Current Ratio
5.14
Quick Ratio
5.14
Forward P/E
-4.36
Price / Sales
—
Enterprise Value
$35.13 M
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | InflaRx N.V. | $1.66 | — | $120.01 M | — | -114.26% | -88.63% | $1.94 / $0.71 | $0.67 |
| 2. | Hoth Therapeutics, Inc. | $0.74 | — | $13.96 M | — | -200.97% | -1.91% | $2.12 / $0.49 | $0.4 |
| 3. | OmniAb, Inc. | $1.55 | — | $237.44 M | — | -24.23% | -23.36% | $2.29 / $1.22 | $1.85 |
| 4. | Oragenics, Inc. | $0.71 | — | $3.19 M | — | -113.05% | -2.44% | $9.6 / $0.5 | $1.94 |
| 5. | FibroBiologics, Inc. | $1.53 | — | $5.37 M | — | -211.82% | -4.19% | $30.6 / $1.03 | $1.85 |
| 6. | Spyre Therapeutics, Inc. | $73.39 | — | $5.76 B | — | -30.53% | -25.17% | $75 / $12.25 | $7.16 |
| 7. | Cocrystal Pharma, Inc. | $1.51 | — | $20.82 M | — | -120.22% | -1.11% | $2.67 / $0.86 | $0.46 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.13 M | -1.15 M | -5.07 M | -2.19 M | -2.91 M | — |
| Net Profit | -2.06 M | -1.1 M | -5.07 M | -2.18 M | -2.9 M | — |
| EPS in Rs | -0.06 | -0.03 | -0.15 | -0.06 | -0.08 | -0.2 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -10.54 M | -12.24 M | -3.94 M | -0.85 M |
| Net Profit | -10.41 M | -16.53 M | -13.07 M | -0.85 M |
| EPS in Rs | -0.3 | -0.48 | -0.38 | -0.02 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.34 M | 1.32 M | 4.77 M | 0.05 M |
| Total Liabilities | 1.43 M | 0.68 M | 1.34 M | 0.99 M |
| Equity | 5.91 M | 0.64 M | 3.44 M | -0.94 M |
| Current Assets | 7.34 M | 1.32 M | 0.44 M | 0.05 M |
| Current Liabilities | 1.43 M | 0.68 M | 1.34 M | 0.99 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -3.69 M | -5.07 M | -3.86 M | -0.47 M |
| Investing CF | — | — | — | — |
| Financing CF | 9.71 M | 6.34 M | 3.86 M | 0.47 M |
| Free CF | -3.69 M | -5.07 M | -3.86 M | -0.47 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -26.48% | -1430.4% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.